Payment overview · 2025
General Payments
$838.06
21 reported records · 7 companies
Healthcare provider profile · identity verified
Nancy Chez, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BRONX, NY · NPI 1760696413
Verified facts
What the public records show
CMS Open Payments records show Nancy Chez, NP received $838.06 in general payments during 2025 across 21 reported records.
ViiV Healthcare Company accounted for 43.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $367.49 | 43.9% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $222.61 | 26.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $118.28 | 14.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $77.73 | 9.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.74 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.12 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.09 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $838.06 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $302.31 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $118.28 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $77.73 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $6.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
223 | 29 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 546 | 91 |
| Metformin Hcl Er | Metformin Hcl | 351 | 57 |
| Gabapentin | Gabapentin | 314 | 55 |
| Lisinopril | Lisinopril | 280 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 54 |
| Losartan Potassium | Losartan Potassium | 237 | 36 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 223 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 212 | 30 |
| Nifedipine Er | Nifedipine | 198 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 34 |
| Omeprazole | Omeprazole | 152 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 23 |
| Jardiance | Empagliflozin | 98 | 13 |
| Famotidine | Famotidine | 96 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 23 |
| Montelukast Sodium | Montelukast Sodium | 94 | 18 |
| Ozempic | Semaglutide | 93 | 14 |
| Meloxicam | Meloxicam | 76 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 73 | 23 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 71 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 67 | 16 |
| Carvedilol | Carvedilol | 61 | 12 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 60 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 12 |
| Ezetimibe | Ezetimibe | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Spironolactone | Spironolactone | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 13 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Metformin Hcl | Metformin Hcl | 47 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 11 |
| Furosemide | Furosemide | 45 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 43 | 14 |
| Valacyclovir | Valacyclovir Hcl | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 41 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Enulose | Lactulose | 27 | suppressed |
| Tivicay | Dolutegravir Sodium | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ztlido | Lidocaine | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Piroxicam | Piroxicam | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Budesonide Er | Budesonide | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Generlac | Lactulose | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $838.06 · 21 records | ViiV Healthcare Company | APRETUDE, AREXVY, BEXSERO, CABENUVA, DOVATO, FREESTYLE LIBRE 3, MAVYRET, PIFELTRO, REPATHA, SHINGRIX, Yeztugo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error